Tag
This article reviews a validated clinical risk model predicting arrhythmic events in patients with RYR2-mediated CPVT receiving beta-blockers, facilitating personalized management to reduce life-threatening arrhythmias.
A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.
A secondary analysis of ABYSS shows that in stable post-MI patients with preserved ejection fraction, higher heart rate remains prognostic and β-blocker interruption increases heart rate by about 10–13 bpm while worsening outcomes across he
A pivotal triple-crossover RCT reveals that while bisoprolol reduces exercise capacity and worsens diastolic markers in nonobstructive HCM, verapamil maintains exercise performance and improves myocardial strain.
An individual‑patient meta‑analysis of five randomized trials (n=17,801) found that beta‑blocker therapy did not reduce death, recurrent MI, or heart failure in patients with recent myocardial infarction and LVEF ≥50% without other indicati
Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy conside
Post hoc analysis of the REBOOT trial shows that withholding or withdrawing beta blockers after myocardial infarction in patients with preserved LVEF (>40%) does not increase short-term or recurrent ischaemic events, challenging current
The REBOOT trial reveals a sex-specific differential effect of beta-blockers after MI, showing increased harm in women with preserved LVEF, challenging current guideline recommendations.
